Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 ...

Recently, Vivek posted a picture of his post-workout meal on his Instagram Stories, showcasing a beautifully arranged plate of roasted sweet potatoes and sprouts. Read Time: 2 min Vivek Dahiya, the ...

The Thiruvananthapuram Rural police believe they have zeroed in on the suspect in the fatal stabbing of Athira, 33, a housewife and mother of a two-year-old child, at her residence at ...

U.S. company Athira Pharma Inc. has agreed to pay $4.07 million to settle allegations that it used its former CEO’s falsified research to secure a federal grant in 2019. The pharmaceutical company was ...

From what we can see, insiders were net buyers in Athira Pharma, Inc.'s (NASDAQ:ATHA ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.

Athira Pharma, a small drugmaker focused on neuroscience, is looking into the different paths it could take to “maximizing stockholder value,” after the company’s most advanced experimental ...

Founded in 2011 under the name M3 Biotechnology, Athira has been trying to develop small molecule drugs that help regenerate nerve cells and slow their erosion from diseases like Alzheimer’s and ...

Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring. Athira, which went public in 2020 ...

“These are not the results we hoped for,” Javier San Martin, MD, Athira’s chief medical officer, acknowledged in a statement. “The lack of clinical decline in the placebo group, combined ...

The latest analyst rating for Athira Pharma (NASDAQ:ATHA) was provided by Mizuho, and Athira Pharma downgraded their neutral rating. The last downgrade for Athira Pharma Inc happened on September ...